Tocilizumab

Resumen

Alternativas con registro en Colombia

• Basiliximab · costo anual estimado $ 2.583.167.050
• Ustekinumab · costo anual estimado $ 36.735.425
• Canakinumab · costo anual estimado $ 356.878.385
• Secukinumab · costo anual estimado $ 60.543.645
• Ixekizumab · costo anual estimado $ 67.164.015
• Guselkumab · costo anual estimado $ 36.824.485
• Risankizumab · costo anual estimado $ 34.575.720
• Espesolimab
• Mirikizumab

Estudios clínicos principales

• A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid A
  Fase 3 · 2010 · 1.262 participantes · Hoffmann-La Roche · NCT01194414
• A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthri
  Fase 3 · 2005 · 1.196 participantes · Hoffmann-La Roche · NCT00106535
• A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Art
  Fase 3 · 2011 · 656 participantes · Hoffmann-La Roche · NCT01232569
• REMDACTA: A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-
  Fase 3 · 2020 · 649 participantes · Hoffmann-La Roche · NCT04409262

Enfermedades relacionadas

• COVID-19
• Artritis reumatoide
• Cáncer (todos)

Fuentes

• Etiqueta FDA (DailyMed): Tofidence
• EMA: Tosmova (previously Tocilizumab STADA and Tofidence)
• EMA: Avtozma